RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES. - BIM-001

Start Date11 Apr 2024

Sponsor / Collaborator

Genetic SpA

NCT06267274

/ RecruitingPhase 1

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

Start Date01 Apr 2024

Sponsor / Collaborator

Amneal Pharmaceuticals, Inc.

[+1]

100 Clinical Results associated with Bimatoprost

100 Translational Medicine associated with Bimatoprost

100 Patents (Medical) associated with Bimatoprost

1,061

Literatures (Medical) associated with Bimatoprost

01 Sep 2025·EUROPEAN JOURNAL OF OPHTHALMOLOGY

Intraoperative optical coherence tomography in glaucoma surgery with Ex-PRESS ^® implant

Article

Author: Platas Moreno, Irene ; Guerrero Altares, Laura ; Morote, Ignacio Jiménez-Alfaro ; Martin-Gutierrez, M Pilar

Introduction:

To present the correct placement of the Ex-PRESS ® implant in the anterior chamber with the intraoperative optical coherence tomography (i-OCT) scan. To the best of our knowledge, this is the first publication to report the use of i-OCT during an Ex-PRESS ® glaucoma implant procedure.

Case report:

We report the case of a phakic, 48 year-old South American male with bilateral advanced pigmentary glaucoma. Our patient was being treated with dorzolamide-timolol eyedrops twice daily and bimatoprost eyedrops once daily in both eyes. Glaucomatous damage in his left eye had progressed and it was then decided to perform filtering surgery in our patient´s left eye, using a P-50 Ex-PRESS ® shunt and two Ologen ® collagen matrix implants. As our patient was phakic, special care was taken to avoid contact with the lens. The correct placement of both subscleral devices was confirmed with the OPMI LUMERA ® 700 microscope, an i-OCT device. i-OCT scans as well as a video recording were performed throughout the surgical procedure.

Conclusion:

I-Oct can help surgeons to locate the correct placement of implants in cases such as corneal opacification or gerontoxon. This instrument is helpful in the training of ophthalmologists. I-OCT can help surgeons to locate the correct placement of implants in cases with media opacity (such as corneal opacification or gerontoxon) or in phakic patients, where it is important to avoid lens contact. This instrument is helpful in the training of ophthalmologists.

14 Aug 2025·Indian Dermatology Online Journal

Vitamin D and its Analogs in Treatment of Mild to Moderate Alopecia Areata: Systematic Review and Meta-Analysis.

Article

Author: Alzabadin, Rakan Abdullah ; Alzakry, Leena Mohammed ; Alsaadoun, Dalal ; Kaliyadan, Feroze ; Rubaian, Nouf F Bin ; Hakami, Turki Hassan ; Alsaati, Ahmed Abdulaziz

BACKGROUND:

Recently, vitamin D3 and its analogs have shown therapeutic potential in the treatment of alopecia areata (AA).

AIM AND OBJECTIVE:

The aim of this study was to evaluate the safety/efficacy of topical/intralesional vitamin D3 and its analogs for treatment of mild-to-moderate AA.

MATERIALS AND METHODS:

We included clinical trials that evaluated topical/intralesional vitamin D3 and its analogs for the treatment of AA. Response rates were defined as either achieving a Score 4 (S4) response on the hair regrowth scale (≥75% regrowth) or reduction in the mean Severity of Alopecia Tool (SALT) score after treatment.

RESULTS:

The overall success rate of vitamin D3 and its analogs in the treatment of mild-to-moderate AA is about 53.75%. Both intralesional and topical vitamin D3 (odds ratio = 3.20; 95% confidence interval (CI): [1.24, 8.24] and mean difference (MD) = 2.11; 95% CI: [-1.10, 5.31], respectively) are effective in the treatment of mild-to-moderate AA. Additionally, topical vitamin D3 analogs had a synergistic effect when used in combination with other treatments including topical corticosteroids and NB-UVB (MD = 0.62; 95% CI: [-0.24, 1.48] and MD = 1.34; 95% CI: [0.96, 1.71]), respectively. Intralesional vitamin D3 showed lower efficacy compared to intralesional corticosteroid and topical bimatoprost (MD = -4.73; 95% CI: [-7.38, -2.08]). No serious adverse events were associated with the use of vitamin D3 and its analogs.

LIMITATIONS:

Small number of randomized clinical trials, lack of baseline vitamin D3 levels and co-morbid autoimmune conditions assessment.

CONCLUSION:

Vitamin D3 and its analogs may serve as a safe, inexpensive alternative for mild-to-moderate patchy AA, either as a mono-therapeutic agent or as an adjuvant for more severe cases.

01 Aug 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation

Article

Author: Kim, Hyun-Kyung ; Sung, Min Kyung ; Shin, Eun Jin ; Kim, Hyung Soo ; Woo, In Suk ; Han, Kyoung-Moon ; Kim, You Kyung

Some prostaglandin F_2α (PGF_2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. However, research on the simultaneous analysis of multiple PGF_2α analogs using HPLC-UV or DAD techniques is limited. In this study, a high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of 11 PGF_2α analogs, optimizing both the analytical column and sample preparation method. Five columns with varying particle sizes, lengths, and packing types were compared to select the optimal analytical column. The separation efficiency of the columns was confirmed by comparing their chromatographic parameters, including retention time, resolution, number of theoretical plates, and height equivalent to a theoretical plate. Solid-phase extraction (SPE) was used to pretreat cosmetic samples, and the washing solvent and cartridge type for the SPE process were optimized. The established HPLC method was validated in terms of linearity, limits of detection and quantification, recovery, accuracy, and precision. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF_2α analogs.

116

News (Medical) associated with Bimatoprost

04 Sep 2025

·www.globenewswire.com

Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed

Press Release Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed Company expects to fully repay existing financial debts in 2026NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approvalGlaukos extends NCX 1728 research agreement Future strategic options under consideration including collaborations or business combinationsQ&A for shareholders available on the Nicox website: Q&A September 4, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it expects to be able to fully repay all existing financial debts in 2026 and provided an update on its portfolio and financial situation. This follows the recent announcements of the licensing of NCX 470 to Kowa, completing our global coverage, and the positive results from our second pivotal Phase 3 clinical trial, Denali. NCX 470 has met the requirements for New Drug Applications (NDA) in the U.S. and China, with NDA submission expected in H1 2026 in the U.S., and subsequently in China. Based on these submissions, the Company expects to have recurrent revenue from 2027, in addition to milestone payments on NDA submission and approval. Costs of the NDA submissions are the responsibility of our partners.“Nicox is a revenue generating biotech with a deep and proven expertise in ophthalmology development, transactions and corporate operations. Following the recent announcement of the licensing deal for NCX 470 with Kowa, which fulfils our global licensing plans, we have also completed the second pivotal Phase 3 clinical trial, Denali, for NCX 470 in the U.S. and China. Our team will be supporting our partners, Kowa and Ocumension, in submitting the NCX 470 New Drug Applications and ensuring broad communication of the product profile and data.” said Gavin Spencer, Chief Executive Officer of Nicox. “We have demonstrated that Nicox can deliver on both the development of major clinical assets and the associated financing, whilst simultaneously implementing commercial solutions. In doing so, we have created long-term revenue streams for the Company, addressed our short-term financial needs and expect to fulfil our obligations to creditors. We believe we are now in a strong position to explore strategic options, including collaborations or business combinations.”Key Future Milestones NCX 470 New Drug Application (NDA) filing in the United States: expected in H1 2026.NCX 470 New Drug Application (NDA) filing in China: expected after submission in the U.S. Results from NCX 470 Phase 3 clinical program in Japan: Program initiated in summer 2025. Managed and financed by Kowa. Financial UpdateNCX 470 is now licensed globally, with milestone payments expected in 2026 and 2027. Royalties on net sales are expected from 2027. Based on the expected upcoming milestones and the repayment of all existing financial debts, the Company is financed into Q3 2026. The Company remains committed to cost control, optimizing resource allocation while maintaining the capabilities required to support our strategic objectives. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company.Portfolio update NCX 470, Nicox’s lead product candidate, is licensed globally to two top-tier pharma partners, Kowa and Ocumension Therapeutics. The first two Phase 3 trials, Mont Blanc and Denali, have met the requirements for submission of NDAs in the U.S. and China. U.S. – based on Nicox’s projections, an NDA with the U.S. Food and Drug Administration (FDA) is expected to be submitted in H1 2026. Kowa is responsible for the costs of the NDA submission.China – an NDA is expected to be filed with the Chinese regulatory authorities by our partner, Ocumension, after the U.S. submission. The costs of filing the NDA are the responsibility of Ocumension.Japan – a Phase 3 confirmatory efficacy and a Phase 3 safety trial have been initiated in Japanese patients. Kowa is responsible for managing the trials, at their cost, and expect to be able to file for a marketing authorisation in Japan based on these trials.Europe – the regulatory strategy is being evaluated. NCX 1728, an NO-donating PDE-5 inhibitor, is being evaluated in a pre-clinical research program exploring indications for the treatment of glaucoma, including neuroprotection, and in the treatment of retinal diseases, under an exclusive research and option to license agreement with Glaukos. Glaukos has paid an extension fee to prolong the period of evaluation of NCX 1728 for the treatment of glaucoma. Evaluation for retinal conditions is also continuing, and is subject to different option conditions.ZERVIATE® (cetirizine ophthalmic solution), 0.24%, is currently commercialized through exclusive licensing agreements in the U.S. by Harrow, Inc. and in China by Ocumension Therapeutics for ocular itching associated with allergic conjunctivitis. VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, is exclusively licensed worldwide to Bausch + Lomb. Nicox sold the royalty revenue from VYZULTA to Soleus Capital in October 2024.NCX 4251: Changes in the U.S. dry eye market suggest that the investment in development may not be justified. NCX 4251 remains available for licensing outside the Chinese market.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_NicoxPipelineAndStrategyUpdateSeptember2025_PR_FINAL

Phase 3License out/inNDA

26 Aug 2025

·www.globenewswire.com

Nicox Announces Shareholder Q&A Webpage Available

Press Release Nicox Announces Shareholder Q&A Webpage AvailableAugust 26, 2025 – release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that a new webpage “Q&A” is available on the company’s website, www.nicox.com, including information on the most frequently asked questions for shareholders in the form of a Q&A about Nicox and its business. The Q&A page can be reached here: Q&A Any investor questions can be addressed to communications@nicox.com.About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese, and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2024” which is available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_Q&AAugust2025_PR_FINAL

21 Aug 2025

·endpoints.news

Nicox eyes FDA submission as ocular hypertension drug passes Phase 3

Nicox’s eye drop candidate has cleared a second Phase 3 trial in conditions related to high blood pressure in the eyes, poising the company for an FDA filing in the first half of 2026. The French biotech’s bimatoprost-based drug, called NCX 470, was just as good as standard of care at reducing intraocular pressure, meeting the primary endpoint of the Denali trial. The standard of care is latanoprost eye drops. The study enrolled 696 patients with open-angle glaucoma or ocular hypertension in the US and China, according to Thursday’s release . NCX 470 previously passed a similarly designed Phase 3 trial called MontBlanc in 2022. Nicox is now preparing for a pre-NDA meeting with the FDA along with its partner Kowa. It also plans to share detailed results from the Denali trial at a future ophthalmology meeting. But NCX 470 didn’t meet the study’s secondary endpoint of time-matched change in intraocular pressure versus latanoprost. The treatment did show “statistical superiority” at three of the six time points measured, but fell short of significance in the overall endpoint. Nicox’s drug was also associated with a higher rate of conjunctival hyperaemia (22.0%) compared with latanoprost (9.2%). This happens when the clear membrane in the white part of the eyeball becomes red due to the dilation of blood vessels. Furthermore, 10.1% of patients receiving NCX 470 discontinued treatment versus 6.6% of latanoprost patients. With Thursday’s data, Nicox is set to receive a €5 million ($5.8 million) milestone from Kowa per a licensing pact inked in July. Under the terms of that deal, Kowa has exclusive rights to develop and commercialize NCX 470 in the US and all other markets except for certain Asian countries. Nixon could get up to €127 million in milestones. Ocumension Therapeutics has the rights to NCX 470 in China, Korea and Southeast Asia.

Phase 3License out/in

100 Deals associated with Bimatoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D02724	Bimatoprost	S01EE03	DB00905

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Takeda Pharmaceutical Co., Ltd.	07 Jul 2009
Glaucoma	Japan	Senju Pharmaceutical Co., Ltd.	07 Jul 2009
Hypotrichosis	United States	AbbVie, Inc.	24 Dec 2008
Glaucoma, Open-Angle	United States	AbbVie, Inc.	16 Mar 2001
Ocular Hypertension	United States	AbbVie, Inc.	16 Mar 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hydrophthalmos	Phase 3	United States	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	France	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Italy	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Philippines	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	Taiwan Province	Allergan UC	01 Sep 2011
Hydrophthalmos	Phase 3	United Kingdom	Allergan UC	01 Sep 2011
Alopecia	Phase 3	Japan	Allergan UC	01 Jul 2011
Cataract	Phase 2	United States	SpyGlass Pharma Inc	13 Oct 2023
Androgenetic Alopecia	Phase 2	United States	Allergan UC	01 Jun 2011
Androgenetic Alopecia	Phase 2	Germany	Allergan UC	01 Jun 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


FDA_CDER Manual	Not Applicable	Glaucoma, Open-Angle \| Ocular Hypertension	-	0.01% ZOLYMBUS	blzpmiuasf(xfnrlldvsl) = OLYMBUS once daily (in the evening) was non-inferior to preserved bimatoprost ophthalmic solution 0.01%. fqjzyuodin (jfpkyoggct ) View more	Positive	09 Sep 2025
				0.01% preserved bimatoprost ophthalmic solution
NCT03850782 (TRITON, Pubmed \| Drugs)	Phase 3	Ocular Hypotension	441	Bimatoprost implant 10 µg	fjhymrloya(hbjsaydwch) = wxtcqfvqqt zbpecfkwgd (ltkuyzgajv, 369 - 485) View more	Positive	22 Feb 2025
NCT04747808 (BusinessWire) Manual	Phase 2	Glaucoma	-	LL-BMT1LL-BMT1 32-µg dose	begfjatszb(dbukrycouk) = iwpjniivep blwizpfiss (tbcmxsbqpx ) View more	Positive	12 Nov 2024
				bimatoprostbimatoprost 0.01%	-
NCT03825380 (CTgov)	Phase 3	Glaucoma, Open-Angle \| Glaucoma	485	Bimatoprost (T4032)	xisxozxtda(pamieuausc) = janubrdlrv ghnupjlgia (ehcjhcchhx, 0.19) View more	-	21 Nov 2023
				Lumigan® (Lumigan®)	xisxozxtda(pamieuausc) = pnbffrzyvu ghnupjlgia (ehcjhcchhx, 0.18) View more
NCT04285580 (CTgov)	Phase 3	Glaucoma, Open-Angle	37	Bimatoprost SR (Bimatoprost SR 10 μg)	bxwkfhfucq(verwzpxegz) = xnmbttkmzo haeonvsfff (fwblgxngqk, 5.65) View more	-	08 Jun 2023
				LUMIGAN (LUMIGAN 0.01%)	bxwkfhfucq(verwzpxegz) = unwotgwjxx haeonvsfff (fwblgxngqk, 5.27) View more
NCT02250651 \| NCT01157364 \| NCT02247804 (Pubmed)	Phase 3	Ocular Hypertension \| Glaucoma, Open-Angle	-	Bimatoprost implant 10 µg	ecxeturpsw(iibulkqzaz) = mbvcfopgna hxfvqymzeo (dskjcdigov )	-	28 May 2022
				Topical timolol maleate 0.5%	ecxeturpsw(iibulkqzaz) = uzkqqhdxui hxfvqymzeo (dskjcdigov )
NCT03850782 (Phase 3b Study, ARVO2022)	Phase 3	Ocular Hypotension	203	Bimatoprost implant	ssqryhzzfg(iemfxfzech) = kluoewrluk fwzvivvhdb (ltubpvtsmn )	-	01 May 2022
ARVO2022	Not Applicable	Glaucoma	122	Bimatoprost SR implantation	kvdppawiav(gftiqrrhmh) = zgajjeqkzs cfztbavqqj (vwyumttfqa )	-	01 May 2022
NCT03891446 (PO080, AAO2021)	Phase 3	Glaucoma, Open-Angle	200	Bimatoprost implant 10μg	kbbbkafkjy(owvummpmrk) = rxlgdayzoq dwhkjwoxyb (ifhazeifyl, 3.6)	Positive	13 Nov 2021
				Bimatoprost implant 15μg	kbbbkafkjy(owvummpmrk) = puuwaenhpo dwhkjwoxyb (ifhazeifyl, 3.2)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bimatoprost

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation